awmsg logo



brivaracetam (Briviact®)


Reference No. 2038

Publication date:
05/10/2016


Appraisal information

brivaracetam (Briviact®) 10 mg film-coated tablet
brivaracetam (Briviact®) 25 mg film-coated tablet
brivaracetam (Briviact®) 50 mg film-coated tablet
brivaracetam (Briviact®) 75 mg film-coated tablet
brivaracetam (Briviact®) 100 mg film-coated tablet
brivaracetam (Briviact®) 10 mg/ml oral solution
brivaracetam (Briviact®) 10 mg/ml solution for injection/infusion


Company: UCB Pharma Ltd
BNF category: Central nervous system
NMG meeting date: 20/07/2016
AWMSG meeting date: 21/09/2016
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 2516
Ministerial ratification: 04/10/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Brivaracetam (Briviact®) is recommended as an option for restricted use within NHS Wales. Brivaracetam (Briviact®) should be restricted to use in the treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines, within its licensed indication as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. Brivaracetam (Briviact®) is not recommended for use within NHS Wales outside of this subpopulation.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download
Final Appraisal Recommendation (FAR)
Download